AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04329715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expedited postoperative activity instructions
Description: Ad lib postoperative activity and return to work recommendations
Study NCT04329715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative activity restructions
Description: Standard conservative postoperative activity and return to work recommendations
Study NCT03882073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified amputation procedure
Description: A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
Study NCT03649165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
Study NCT03882073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard amputation procedure
Description: Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
Study NCT02413294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Re-Timer glasses
Description: Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
Study NCT01955044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCPUFA supplement
Study NCT03649165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
Study NCT03649165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single 500mg dose of acetaminophen at the same time.
Study NCT01955044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04759079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Needles
Description: Acupuncture Needles placement at the PC6 in association to anti-emetic medication
Study NCT04759079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic Drug
Description: Administration of Anti-emetic medication without acupuncture
Study NCT04470193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyChildCMC app
Description: Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
Study NCT04759079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic Drug
Description: Administration of Anti-emetic medication without acupuncture
Study NCT03612804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsigned note to provider about cessation medication prescription
Description: For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.
Study NCT03612804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Telephone Counseling from VA Quitline
Description: Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
Study NCT03105128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by intravenous infusion
Study NCT03105128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: Risankizumab administered by intravenous infusion
Study NCT03105128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: Risankizumab administered by subcutaneous (SC) injection
Study NCT00629200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Stibogluconate
Description: 400 mg/m\^2 IV daily on days 1-5.
Study NCT00629200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alpha-2b
Description: 3x10\^6 units subcutaneously three times weekly
Study NCT04682756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The model of machine learning
Description: Early diagnosis of NTEMI patients by machine learning model
Study NCT01711307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative
Study NCT01711307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-operative
Description: casting within 48 hrs
Study NCT01243801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
Study NCT01243801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
Study NCT03955640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03955640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia Treatment
Description: Undergo hyperthermia treatment
Study NCT03955640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03955640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02875665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko(TM) device
Description: The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
Study NCT00984087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS with Neurostar TMS Therapy System
Description: 20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
Study NCT01242150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCPAP by helmet
Description: The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
Study NCT01242150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP by facial mask
Description: The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
Study NCT03862170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
Study NCT03862170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Study NCT00431795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (Caelyx)
Description: Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
Study NCT00431795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles
Study NCT02796976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training or control condition
Description: Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
Study NCT03161691 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous treatment of ischemic stroke
Description: An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
Study NCT01469949 — intervention group
Intervention type: OTHER
Intervention: Watching or imagining movement
Description: Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
Study NCT03439904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
Study NCT02404233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat
Description: Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
Study NCT02404233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilpivirine
Description: Rilpivirine tablet 25 mg once daily taken with food
Study NCT02885311 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivation Enhancement Therapy
Description: Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
Study NCT02885311 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified Behavioral Self-Control Therapy
Description: Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
Study NCT02885311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
Study NCT02885311 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Advice
Description: Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
Study NCT02885311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referral to specialty substance use disorder treatment
Description: Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
Study NCT00127647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast sodium; 5 mg, 10 mg QD 2-weeks.
Study NCT00127647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pranlukast
Description: Pranlukast 225 mg BID 2-weeks.
Study NCT00768651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
Study NCT00768651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
Study NCT04367376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: central postroanterion mobilization on the most painful vertebral level at the lumbar spine
Study NCT04367376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual therapy
Study NCT04367376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumental manual therapy
Description: instrumental manual therapy
Study NCT03357549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
Study NCT03357549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding education
Description: It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
Study NCT00580177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein mesh
Description: The different techniques are compared and evaluated according to primary and secondary objectives.
Study NCT00580177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PerFix Plug®
Description: The different techniques are compared and evaluated according to primary and secondary objectives.
Study NCT00580177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene® Hernia System
Description: The different techniques are compared and evaluated according to primary and secondary objectives.
Study NCT00789477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Photocoagulation
Description: laser every 16 weeks as needed
Study NCT00789477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Study NCT00901537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and Cisplatin
Description: We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
Study NCT01778387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair
Description: Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
Study NCT02432287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
Study NCT02432287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: there is no other name we used for the placebo
Study NCT01245426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 2mg
Description: oral inhalation
Study NCT01245426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 4mg
Description: oral inhalation
Study NCT01245426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW870086 Placebo
Description: oral inhalation
Study NCT01245426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 1mg
Description: oral inhalation
Study NCT01245426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086 3mg
Description: oral inhalation
Study NCT03833674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily AIH Block
Description: Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
Study NCT03833674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham dAIH Block
Description: Daily sessions of sham dAIH which includes breathing room air (21% O2)
Study NCT03185663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traction-stuck
Description: continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
Study NCT03185663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: a pillow between the legs
Description: setting up a pillow between the legs before the care
Study NCT03701711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study.
Study NCT04812574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periurethral injection
Description: Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
Study NCT04812574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic (10%) saline
Description: Periurethral hypertonic saline (10%)
Study NCT05478187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QWalk Study Group
Description: 10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)